乌司奴单抗治疗难治性克罗恩病的临床、内镜和影像学结局:多中心队列的真实世界经验
这项回顾性多中心队列研究纳入2011至2016年间接受乌司奴单抗治疗的167例克罗恩病患者,其中95.2%曾抗TNF治疗失败。3、6、12个月临床缓解率分别为15.0%、25.2%、27.9%,6个月和12个月内镜或影像学应答率分别为54.5%和55.8%。作者认为乌司奴单抗是抗TNF失败克罗恩病诱导和维持临床、内镜及影像学应答的有效治疗选择。
要点
- 167例克罗恩病患者中95.2%(159/167)既往抗TNF治疗失败。
- 3、6、12个月临床应答率分别为38.9%、60.3%、59.5%,缓解率分别为15.0%、25.2%、27.9%。
- 6个月和12个月内镜或影像学应答率分别为54.5%(67/123)和55.8%(48/86)。
核心结论
- 乌司奴单抗是抗TNF治疗失败的克罗恩病患者诱导和维持临床、内镜及影像学应答的有效治疗选择。
研究设计与样本
- 回顾性多中心队列研究,纳入2011年至2016年间接受乌司奴单抗治疗的克罗恩病患者共167例。
主要发现
- 95.2%(159/167)的患者既往抗TNF治疗失败,中位随访45.6周(IQR:24.4-88.9)。
- 3个月时临床应答为38.9%(65/167),临床缓解为15.0%(25/167)。
- 6个月时临床应答为60.3%(91/151),临床缓解为25.2%(38/151)。
- 12个月时临床应答为59.5%(66/111),临床缓解为27.9%(31/111)。
- 6个月时内镜或影像学应答为54.5%(67/123),12个月时为55.8%(48/86)。
关键数值与推荐
- 临床应答定义为Harvey Bradshaw指数(HBI)较基线降低≥3分,临床缓解定义为HBI≤4分。
- 客观应答定义为内镜或影像学评估的克罗恩病改善,客观缓解定义为内镜下黏膜愈合或影像学评估炎症参数完全消退。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ustekinumab is a monoclonal antibody targeting interleukins-12 and -23, with efficacy in Crohn's disease (CD) demonstrated in clinical trials. AIM: To assess the real-world clinical, endoscopic and radiographic response and remission outcomes achieved with ustekinumab in medically-refractory CD. METHODS: A retrospective multicentre cohort study was performed on CD patients receiving ustekinumab between 2011 and 2016. The primary outcome was achievement of clinical and objective steroid-free response and remission at 3, 6 and 12 months. Clinical response and remission were defined by reduction in Harvey Bradshaw Index (HBI) of ≥3 points and an HBI ≤4 points respectively. Objective response was defined by improvement in endoscopic or radiographic CD, as assessed by ileocolonoscopy, contrast-enhanced ultrasound or CT/MR enterography. Objective remission was defined by endoscopic mucosal healing or complete resolution of inflammatory parameters on radiographic assessment. RESULTS: A total of 167 CD patients were treated with ustekinumab. 95.2% (159/167) previously failed anti-TNF therapy. Median follow-up was 45.6 weeks (IQR: 24.4-88.9). At 3 months, clinical response was achieved in 38.9% (65/167) and remission in 15.0% (25/167) of patients. At 6 months, clinical response was achieved in 60.3% (91/151) and remission in 25.2% (38/151) of patients. At 12 months, clinical response was achieved in 59.5% (66/111) and remission in 27.9% (31/111) of patients. Endoscopic or radiographic response was demonstrated in 54.5% (67/123) at 6 months and 55.8% (48/86) of patients at 12 months. CONCLUSIONS: Ustekinumab is an effective therapeutic option for inducing and maintaining clinical, endoscopic and radiographic response in patients with Crohn's disease failing anti-TNF therapy.
引用
- Ma C, Fedorak RN, Kaplan GG, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017. PMID: 28252210. doi:10.1111/apt.14016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。